Zenith Drugs, which was entirely a fresh equity issue of 51.48 lakh shares, received a healthy response from investors. The issue was subscribed 179 times, driven by strong interest across categories. The net proceeds will be used for the purchase of machinery and setting up a new plant, existing manufacturing block upgradation, working capital requirements, and general corporate purposes.
